CR20180529A - Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada - Google Patents

Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada

Info

Publication number
CR20180529A
CR20180529A CR20180529A CR20180529A CR20180529A CR 20180529 A CR20180529 A CR 20180529A CR 20180529 A CR20180529 A CR 20180529A CR 20180529 A CR20180529 A CR 20180529A CR 20180529 A CR20180529 A CR 20180529A
Authority
CR
Costa Rica
Prior art keywords
complement
factor antibodies
antibodies
crossed
references
Prior art date
Application number
CR20180529A
Other languages
English (en)
Inventor
Sandip; Panicker
Tony Sangyoung; Byun
Karen Sue; Christopherson
Graham; Parry
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of CR20180529A publication Critical patent/CR20180529A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente descripción proporciona anticuerpos¬ anti-factor Bb del complemento y composiciones que comprenden los anticuerpos. Los anticuerpos anti-Bb son útiles para el tratamiento de trastornos mediados¬ por el complemento. La presente descripción proporciona métodos para el tratamiento de trastornos mediados ¬por el complemento
CR20180529A 2016-04-04 2017-04-03 Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada CR20180529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04
PCT/US2017/025784 WO2017176651A1 (en) 2016-04-04 2017-04-03 Anti-complement factor bb antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CR20180529A true CR20180529A (es) 2019-03-21

Family

ID=60000646

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180529A CR20180529A (es) 2016-04-04 2017-04-03 Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada

Country Status (23)

Country Link
US (2) US10934347B2 (es)
EP (1) EP3452510A4 (es)
JP (3) JP6967528B2 (es)
KR (1) KR20190003951A (es)
CN (2) CN109563158B (es)
AU (1) AU2017246794A1 (es)
BR (1) BR112018070357A2 (es)
CA (1) CA3019332A1 (es)
CL (1) CL2018002810A1 (es)
CO (1) CO2018010827A2 (es)
CR (1) CR20180529A (es)
DO (1) DOP2018000219A (es)
EA (1) EA201892225A1 (es)
EC (1) ECSP18082302A (es)
IL (2) IL262010B (es)
MA (1) MA44878A (es)
MX (2) MX2018012176A (es)
MY (1) MY194603A (es)
PE (1) PE20190209A1 (es)
PH (1) PH12018502137A1 (es)
SG (1) SG11201808525UA (es)
TN (1) TN2018000341A1 (es)
WO (1) WO2017176651A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017246794A1 (en) 2016-04-04 2018-10-25 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
CA3043261A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
US11331372B2 (en) * 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
TWI823868B (zh) 2017-10-11 2023-12-01 美商生物維瑞提夫美國公司 誘導補體活性之方法
WO2019126356A1 (en) * 2017-12-19 2019-06-27 The University Of North Carolina At Chapel Hill Methods and compositions for delivery of viral vectors across the blood-brain barrier
KR20220042128A (ko) * 2019-06-27 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도
WO2021167949A1 (en) * 2020-02-18 2021-08-26 Children's Hospital Medical Center Compositions and methods for treating liver disease
AR121881A1 (es) * 2020-04-20 2022-07-20 Genzyme Corp Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
RU2162342C2 (ru) 1993-10-25 2001-01-27 Кэнджи Инк. Рекомбинантный аденовирусный вектор и способы его применения
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
KR20060099543A (ko) 1994-12-09 2006-09-19 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
AU4188196A (en) 1994-12-22 1996-07-10 Nissan Chemical Industries Ltd. Organobismuth derivatives and process for producing the same
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
KR20010015856A (ko) 1997-12-12 2001-02-26 마크로메드 인코퍼레이션 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜)
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
AU2005212369B2 (en) 2004-02-10 2011-06-23 Musc Foundation For Research Development Inhibition of factor B, the alternative complement pathway and methods related thereto
EP1771205B1 (en) 2004-06-18 2016-10-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
RU2456298C2 (ru) * 2005-12-20 2012-07-20 ЭсБиАй БАЙОТЕК КО., ЛТД. Антитело против ilt17
US8981060B2 (en) * 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
EP2209807A1 (en) * 2007-11-08 2010-07-28 Genentech, Inc. Anti-factor b antibodies and their uses
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
MX2011005964A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados terapeuticos de peptidos y sus usos.
CA2776144C (en) 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
KR20140093964A (ko) 2011-10-27 2014-07-29 엔케이티 테라퓨틱스 인코포레이티드 iNKT에 대한 인간화 항체
EP2817338B1 (en) 2012-02-24 2017-07-26 AbbVie Stemcentrx LLC Dll3 modulators and methods of use
JP6244350B2 (ja) * 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
AU2014218730B2 (en) 2013-02-22 2018-12-13 Abbvie Stemcentrx Llc Novel antibody conjugates and uses thereof
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
AU2015223056B2 (en) * 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
EA201890285A1 (ru) 2015-07-13 2018-08-31 Сайтомкс Терапьютикс, Инк. Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
AU2017246794A1 (en) 2016-04-04 2018-10-25 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
TWI823868B (zh) 2017-10-11 2023-12-01 美商生物維瑞提夫美國公司 誘導補體活性之方法
AR121881A1 (es) 2020-04-20 2022-07-20 Genzyme Corp Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos

Also Published As

Publication number Publication date
CO2018010827A2 (es) 2018-11-22
PE20190209A1 (es) 2019-02-07
MX2018012176A (es) 2019-02-07
EP3452510A4 (en) 2020-01-15
MA44878A (fr) 2019-03-13
CN116790614A (zh) 2023-09-22
CL2018002810A1 (es) 2019-03-15
JP6967528B2 (ja) 2021-11-17
US10934347B2 (en) 2021-03-02
MY194603A (en) 2022-12-06
CN109563158B (zh) 2022-08-09
EP3452510A1 (en) 2019-03-13
CA3019332A1 (en) 2017-10-12
ECSP18082302A (es) 2019-01-31
JP7326393B2 (ja) 2023-08-15
MX2023007149A (es) 2023-06-28
US20210221877A1 (en) 2021-07-22
BR112018070357A2 (pt) 2019-01-29
CN109563158A (zh) 2019-04-02
DOP2018000219A (es) 2019-03-31
PH12018502137A1 (en) 2019-09-23
EA201892225A1 (ru) 2019-09-30
IL295288A (en) 2022-10-01
JP2021191789A (ja) 2021-12-16
KR20190003951A (ko) 2019-01-10
IL262010B (en) 2022-09-01
IL262010A (en) 2018-10-31
TN2018000341A1 (en) 2020-06-15
SG11201808525UA (en) 2018-10-30
IL295288B1 (en) 2024-04-01
US11851482B2 (en) 2023-12-26
US20190153079A1 (en) 2019-05-23
AU2017246794A1 (en) 2018-10-25
JP2019513726A (ja) 2019-05-30
JP2023139289A (ja) 2023-10-03
WO2017176651A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
CR20180529A (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
UY37026A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP17023281A (es) Inhibidores de mk2 y sus usos
UY37391A (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
CL2016002281A1 (es) Anticuerpos de il-21
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
ECSP19008417A (es) Anticuerpos con inmunogenicidad baja y usos de estos
ECSP17003946A (es) Anticuerpos antagonistas del interferón alfa y omega
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo